$JNJ

JOHNSON & JOHNSON

12
16
0

No SEC Form 4 filings for $JNJ in the last 30 days.

Med

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

The article says President Trump’s Most-Favored-Nation (MFN) drug pricing policy would cap U.S. government reimbursement for certain medicines near prices in other developed countries, potentially pressuring drugmakers’ U.S. sales and profits. It highlights Johnson & Johnson, forecasting $100.8B revenue this year (midpoint, +7% y/y), and Roche, citing a pipeline and a planned SAGA Diagnostics acquisition costing up to $595M.

New Jersey Rep. Tom Kean Jr. ditched Congress for 75 days citing illness. Someone went digging and found out exactly what he's been up to.

New Jersey Rep. Tom Kean Jr. has been absent from Congress for 75 days, citing illness, but records cited by The New Republic and NOTUS say he traveled and traded stocks during the period. He skipped 88 House votes since March 5. NOTUS reports trades in Amcor, Chubb, First Citizens BancShares, Johnson & Johnson, and PepsiCo totaling $50,008–$190,000.

Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market

The article says the “Dividend King” screen requires annual dividend increases for at least 50 straight years and notes the list spans multiple sectors. It argues Procter & Gamble (PG) is a defensive consumer-staples option with a ~2.95% yield, but highlights Johnson & Johnson (JNJ) as a diversified healthcare Dividend King with a ~2.22% yield and dividend growth of ~5.7% annualized over the past decade, while warning JNJ trades at valuation premiums versus its five-year averages and faces talcu

JNJ news & sentiment — JOHNSON & JOHNSON | alphai